florbetaben (18f)
Various (V09)Various (V09) compound in A.C.O.M. - Advanced's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
pharma · Cancer on the prostatic bed · Prostate cancer at risk of developing metastatic lesions
A.C.O.M. - Advanced
A.C.O.M. - Advanced Center Oncology
A.C.O.M. - Advanced drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 2
- Drugs
- 4
- Patents
- 1
A.C.O.M. - Advanced pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
A.C.O.M. - Advanced drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to A.C.O.M. - Advanced in public FDA and regional records.
-
netarsudil
Sensory organs (S01)US regulatory status: approved. Mechanism: Rho-associated protein kinase inhibitor.
- Mechanism
- Rho-associated protein kinase inhibitor
-
Development asset linked to A.C.O.M. - Advanced in public FDA and regional records.